Literature DB >> 33987284

Postoperative adjuvant EGFR-TKIs for resected EGFR-mutant NSCLC-opportunities and obstacles.

Brielle A Parris1, Steven Leong1,2, Henry Marshall1,2, Ian A Yang1,2, Rayleen V Bowman1,2, Kwun M Fong1,2.   

Abstract

Entities:  

Year:  2021        PMID： 33987284      PMCID： PMC8105855          DOI： 10.21037/atm-2020-133

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  24 in total

Review 1.  Gastrointestinal Stromal Tumors.

Authors:  Margaret von Mehren; Heikki Joensuu
Journal:  J Clin Oncol       Date:  2017-12-08       Impact factor: 44.544

2.  Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study.

Authors:  Ning Li; Wei Ou; Xiong Ye; Hai-Bo Sun; Liang Zhang; Qin Fang; Song-Liang Zhang; Bao-Xiao Wang; Si-Yu Wang
Journal:  Ann Surg Oncol       Date:  2014-03-01       Impact factor: 5.344

3.  Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.

Authors:  Karen Kelly; Nasser K Altorki; Wilfried E E Eberhardt; Mary E R O'Brien; David R Spigel; Lucio Crinò; Chun-Ming Tsai; Joo-Hang Kim; Eun Kyung Cho; Philip C Hoffman; Sergey V Orlov; Piotr Serwatowski; Jiuzhou Wang; Margaret A Foley; Julie D Horan; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2015-08-31       Impact factor: 44.544

4.  EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).

Authors:  Anita Midha; Simon Dearden; Rose McCormack
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

5.  Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study.

Authors:  Wen-Zhao Zhong; Ke-Neng Chen; Chun Chen; Chun-Dong Gu; Jun Wang; Xue-Ning Yang; Wei-Min Mao; Qun Wang; Gui-Bin Qiao; Ying Cheng; Lin Xu; Chang-Li Wang; Ming-Wei Chen; Xiaozheng Kang; Wanpu Yan; Hong-Hong Yan; Ri-Qiang Liao; Jin-Ji Yang; Xu-Chao Zhang; Qing Zhou; Yi-Long Wu
Journal:  J Clin Oncol       Date:  2019-06-13       Impact factor: 44.544

6.  Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.

Authors:  Wen-Zhao Zhong; Qun Wang; Wei-Min Mao; Song-Tao Xu; Lin Wu; Yi Shen; Yong-Yu Liu; Chun Chen; Ying Cheng; Lin Xu; Jun Wang; Ke Fei; Xiao-Fei Li; Jian Li; Cheng Huang; Zhi-Dong Liu; Shun Xu; Ke-Neng Chen; Shi-Dong Xu; Lun-Xu Liu; Ping Yu; Bu-Hai Wang; Hai-Tao Ma; Hong-Hong Yan; Xue-Ning Yang; Qing Zhou; Yi-Long Wu
Journal:  Lancet Oncol       Date:  2017-11-21       Impact factor: 41.316

7.  ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection.

Authors:  Yi-Long Wu; Roy S Herbst; Helen Mann; Yuri Rukazenkov; Marcelo Marotti; Masahiro Tsuboi
Journal:  Clin Lung Cancer       Date:  2018-05-01       Impact factor: 4.785

8.  Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy.

Authors:  Siyang Feng; Yuanyuan Wang; Kaican Cai; Hua Wu; Gang Xiong; Haofei Wang; Ziliang Zhang
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240

9.  Differential effects of adjuvant EGFR tyrosine kinase inhibitors in patients with different stages of non-small-cell lung cancer after radical resection: an updated meta-analysis.

Authors:  Di Lu; Zhizhi Wang; Xiguang Liu; Siyang Feng; Xiaoying Dong; Xiaoshun Shi; He Wang; Hua Wu; Gang Xiong; Haofei Wang; Kaican Cai
Journal:  Cancer Manag Res       Date:  2019-04-02       Impact factor: 3.989

10.  Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study.

Authors:  Wenjing Yang; Yibo Gao; Xuelian Li; Jing Zhang; Tiejun Liu; Xiaoli Feng; Hao Pan; Xiaofan Yang; Shuanghua Xie; Xiaoshuang Feng; Zhangyan Lv; Yonggang Wang; Zhaoli Chen; Jie He
Journal:  World J Surg Oncol       Date:  2017-11-06       Impact factor: 2.754
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.